These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28912071)

  • 1. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study.
    Martelli G; Miceli R; Folli S; Guzzetti E; Chifu C; Maugeri I; Ferranti C; Bianchi G; Capri G; Carcangiu ML; Paolini B; Agresti R; Ferraris C; Piromalli D; Greco M
    Eur J Surg Oncol; 2017 Nov; 43(11):2012-2020. PubMed ID: 28912071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study.
    Martelli G; Barretta F; Miceli R; Folli S; Maugeri I; Listorti C; Scaperrotta G; Baili P; Pruneri G; Capri G; Ferraris C
    Ann Surg; 2022 Nov; 276(5):e544-e552. PubMed ID: 33065651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.
    Kahler-Ribeiro-Fontana S; Pagan E; Magnoni F; Vicini E; Morigi C; Corso G; Intra M; Canegallo F; Ratini S; Leonardi MC; La Rocca E; Bagnardi V; Montagna E; Colleoni M; Viale G; Bottiglieri L; Grana CM; Biasuz JV; Veronesi P; Galimberti V
    Eur J Surg Oncol; 2021 Apr; 47(4):804-812. PubMed ID: 33092968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
    Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
    Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of sentinel node biopsy alone in early breast cancer without further axillary dissection in patients with negative sentinel node.
    Soni NK; Spillane AJ
    ANZ J Surg; 2005 May; 75(5):292-9. PubMed ID: 15932439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.
    van der Heiden-van der Loo M; de Munck L; Sonke GS; van Dalen T; van Diest PJ; van den Bongard HJ; Peeters PH; Rutgers EJ
    Eur J Cancer; 2015 May; 51(8):915-21. PubMed ID: 25857549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.
    Jones JL; Zabicki K; Christian RL; Gadd MA; Hughes KS; Lesnikoski BA; Rhei E; Specht MC; Dominguez FJ; Smith BL
    Am J Surg; 2005 Oct; 190(4):517-20. PubMed ID: 16164912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
    Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
    Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
    Meretoja TJ; Joensuu H; Heikkilä PS; Leidenius MH
    J Surg Oncol; 2010 Nov; 102(6):649-55. PubMed ID: 20976732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sentinel node biopsy for breast cancer patients at the Bács-Kiskun County Teaching Hospital].
    Cserni G; Rajtár M; Boross G; Sinkó M; Svébis M; Baltás B; Ambrózay E; Szúcs M
    Orv Hetil; 2002 Mar; 143(9):437-46. PubMed ID: 12013684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.
    Veronesi U; Viale G; Paganelli G; Zurrida S; Luini A; Galimberti V; Veronesi P; Intra M; Maisonneuve P; Zucca F; Gatti G; Mazzarol G; De Cicco C; Vezzoli D
    Ann Surg; 2010 Apr; 251(4):595-600. PubMed ID: 20195151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up.
    Ogawa Y; Ikeda K; Watanabe C; Kamei Y; Tokunaga S; Tsuboguchi Y; Inoue T; Fukushima H; Ichiki M
    Surg Today; 2018 Jan; 48(1):87-94. PubMed ID: 28647776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is my patient an appropriate candidate for sentinel node biopsy? Less axillary surgery, for the right patients. Critical review and grades of recommendation.
    Bessa JF; Novita GG; Testa L; Freitas-Junior R; Marta GN
    Surg Oncol; 2024 Jun; 54():102064. PubMed ID: 38518660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.
    Patel NA; Piper G; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Aug; 70(8):696-9; discussion 699-700. PubMed ID: 15328803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.